《新股表現》藥明合聯(02268.HK)暗盤高開11.7%報23元
根據輝立交易平台顯示,明天掛牌的藥明合聯(02268.HK)暗盤高開11.7%報23元,高低見24.85元/22.7元,現報24.6元,較上市價20.6元,高19%,成交145萬股。
由藥明生物(02269.HK)分拆的藥明合聯,專注於全球抗體藥物偶聯物(ADC)及更廣泛生物偶聯藥物市場的領先合同研究、開發及製造組織(CRDMO),亦提供全面綜合服務。今次在港上市合共發售逾1.784億股,並已引入7名基石機構投資者,合共認購1.14億股;其中10%公開發售獲近49倍超購,已啟動回撥機制佔比增至30%,認購一手中籤率13%;股份以招股範圍(19.9-20.6元)上限定價,料集資淨額約34.83億元,主要用作在新加坡興建設施及擴大在中國的抗體中間體產能,以及選擇性尋求戰略聯盟、投資及收購機會等。上市聯席保薦人為大摩、高盛及摩通。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.